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Background/Aims: T-lymphocyte reactivity against viral antigens may represent the only immunological marker of
host contact with a virus. Aim of the present study was to investigate whether vertical exposure to hepatitis C virus
(HCV) could activate HCV-specific T-cell responses that may represent a biomarker of previous contact with the virus,
and possibly contribute to the low rate of vertical HCV transmission.
Methods: We studied 28 children born from chronically HCV-infected mothers. HCV-specific activation and
proliferation of CD4C-lymphocytes and cytokine production were evaluated in cultures of peripheral blood
mononuclear cells (PBMCs) stimulated in vitro with HCV-peptides.
Results: HCV-specific CD4C-cell reactivity was observed in 20 out of the 28 children (71%). The proliferation of
HCV-specific CD4C-cells was more frequent and vigorous in children than in their mothers. In children, but not in the
mothers, activation of CD4C-cells upon stimulation with HCV-peptides was directly correlated with proliferation.
Early upon stimulation with HCV-peptides, lymphocytes from children produced lower levels of IL-10 than
lymphocytes from the mothers.
Conclusions: Vertical exposure to HCV induces the development of viral-specific CD4C-cell-mediated immune
responses, possibly endowed with protective function against infection, which may contribute to the low rate of vertical
HCV transmission.
q 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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cytometry1. Introduction
Exposure to hepatitis C virus (HCV) of children born
from HCV-infected mothers can take place in uterus,
transplacentally at any time during pregnancy, during
labour, or after birth. The rate of mother-to-child trans-
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[1–5]. The mechanisms underlying the low rate of vertical
transmission of HCV remain unknown.
Commonly, immune responses against viruses are
defined as production of specific antibodies. However, T
lymphocytes play a major role in directing effector
immune responses to viruses, and following viral exposure
the host may develop a T-cell mediated immunity in the
absence of humoral responses. Indeed, in a cohort of
accidentally exposed adults, HCV-specific helper and
cytotoxic T-cell responses were detectable in the blood
of most subjects in the absence of HCV-specificJournal of Hepatology 43 (2005) 394–402www.elsevier.com/locate/jheplished by Elsevier B.V. All rights reserved.
Table 1
Summary of mother and child characteristics
Variable Mothers (nZ23) Children (nZ28)
Patient demographics
Male (%) NA 17 (61)
Age, mean (range)a 33 years (27–41) 28 months (12–51)
Laboratory results
Positive HCV antibodies, n (%) 23 (100) 3 (11)
Positive HCV RNA, n (%) 23 (100) 2 (7)
Genotype 1a, n (%) 6 (26) 0 (0)
Genotype 1b, n (%) 3 (13) 1 (4)
Genotype 1a/1b, n (%) 2 (9) 0 (0)
Genotype 2a/2c, n (%) 4 (17) 1 (4)
Genotype 3a, n (%) 8 (35) 1 (4)
ALT !40 U/l, n 18 26
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viral antigens may represent the only immunological
marker of host contact with the virus, and may endow the
host with protective immunity against HCV.
Aim of the present study was to investigate whether, in
children born from HCV-infected mothers, vertical exposure
activates HCV-specific T-cell responses that may represent a
biomarker of previous contact with the virus and possibly
contribute to the low rate of vertical HCV transmission. To
this purpose, we studied 23 HCV-infected mothers and their
28 children aging 1–4 years. The reactivity of HCV-specific
CD4C-cells was evaluated in cultures of peripheral blood
mononuclear cells (PBMCs) stimulated in vitro with four
individually tested HCV-peptides.
ALT O40 U/l, n (range) 5 (45–70) 3 (50–62)
Method of delivery
Vaginal, n (%) NA 25 (89)
Cesarean, n (%) NA 3 (11)
Neonatal feeding
Breast, n (%) NA 19 (68)
Bottle, n (%) NA 9 (32)
NA, not applicable; ALT, alanine aminotransferase.
a Age and laboratory results referred to the time of immunological
evaluation.2. Materials and methods
2.1. Study population
Twenty-three women with chronic HCV-infection and their 28 children
were included in the study. At delivery, all mothers were positive for anti-
HCV antibody and HCV-RNA and negative for HIV. All children
underwent clinical examination at birth, every 3 months during the first
year of life and every 6 months thereafter, according to a standard
laboratory and clinical protocol.
Twenty-five (89%) children did not acquire infection. This was
demonstrated by the fact that they lost the passive antibody by 1 year of
age, were persistently HCV-RNA negative and showed normal clinical
and liver function examinations. Three children were deemed infected
with persistent detection of HCV-RNA starting from 3 months of age
and persistent anti-HCV antibody beyond 18 months of age. Viral
genotypes of the infected children (1b, 2a/2c, 3a) matched those of their
mothers.
Immunological evaluation was performed at a single time point on fresh
peripheral blood samples simultaneously obtained from children aged 1 to 4
years and from their mothers. Mother and child characteristics at this time
are summarized in Table 1. Sixteen healthy women age-matched with the
mothers (mean 32 years, range 25–43) were included as controls. Ethics
approval was obtained from the local Institutional Review Committee and a
signed informed consent was obtained from all participants.
2.2. Virological methods
Anti-HCV antibodies were assayed by a third generation enzyme-linked
immunosorbent assay (HCV 3.0 ELISA, Ortho Clinical Diagnostic System,
Raritan, NJ). Reactive samples were confirmed using a supplemental
recombinant immunoblot assay (RIBA 3.0, Ortho Clinical Diagnostic
Systems). HCV-RNA was detected by an in-house RT-PCR assay with
nested primers of the 5 0 non-coding region of the HCV genome. HCV-
genotype was determined using the Innogenetic Line Probe assay (Inno
Lipa HCVII, Immunogenetics, Ghent, Belgium).
2.3. HCV-peptides
Thirty-eight peptides spanning the entire HCV-polyprotein were
designed, which corresponded to the GenBank published sequences of
HCV-1b strain. The peptides were chosen on the basis of their ability
to bind to the most common HLA molecules present in the Italian
population, as predicted by computer algorithms (SYFPEITHI, http://www.
uni-tuebingen.de/uni/kxi; BIMAS, http://bimas.dcrt.nih.gov/molbio/hla_
bind/index.html). The peptides were synthesized by solid-phase methods
on a 433A automated peptide synthesizer (PE Applied Biosystems, Foster
City, CA), as previously described [7]. Peptide purity was verified by
reverse-phase high-performance liquid chromatography and electron spraymass spectrometry. The synthetic peptides were lyophilized, reconstituted
in DMSO at 50 mg/ml, and diluted in RPMI 1640, as needed. One peptide
from the core (C39-63), one from the envelope (E1238–262), and two from
the non-structural region (NS31384–1401, and NS31406–1415) resulted to
be the most immunogenic in preliminary experiments, and were therefore
used along this study to analyze HCV-specific T-cell reactivity. A non-
antigenic HIV peptide (p23) was used as negative control [8].2.4. In vitro assays for CD4C-cell reactivity
Peripheral blood mononuclear cells (PBMCs), isolated from fresh blood
by Ficoll density gradient centrifugation (Cedarlane, Hornby, Canada) were
cultured in RPMI 1640 supplemented with 10% human AB serum at 2!
105/200 ml/well in 96-well U-bottomed plates (Corning, Corning, NY). To
assess immune-competence the responses induced by a polyclonal mitogen
(PHA) were evaluated. PBMCs were cultured without stimulation, or were
stimulated with PHA (M form, Sigma Chemicals Co., St Louis, MO) or
with the selected HCV-peptides at 10 mg/ml. For inhibition experiments,
PBMCs were preincubated with various amounts of neutralizing mAb
against IL-10 (clone JES3-9D7, PharMingen, San Diego, CA) for 30 min,
and the inhibitor was left in culture for the entire stimulation period.
Cultures were performed in duplicates. In all cases, 5-bromo-2 0-
deoxyuridine (BrdU, 20 mM; Sigma Chemicals) was added to each well
during the last 6 h of culture, and lymphocyte proliferation was assessed by
flow cytometry as BrdU incorporation by CD4C lymphocytes, as described
elsewhere [9,10]. Briefly, supernatants were stored at K20 8C for further
analyses and cells were double-stained with anti-CD4 and -CD25 mAbs
(Caltag, Burlingame, CA). Following cell fixation, permeabilization and
partial DNA denaturation, cells were directly stained with anti-BrdU mAb
(Becton Dickinson, San Jose, CA). Cells were collected and analyzed using
a FACScan (Becton Dickinson) within 24 h. The degree of HCV-specific
CD4C-cell proliferation was expressed as proliferation index (PI),
calculated from the fraction of CD25C/BrdUC CD4C cells found with
antigen divided by that found without antigen. A representative analysis is
shown in Fig. 1. A significant PI in response to the HCV-peptides was
defined as being O2.75, which was the cut-off value greater than the mean
PI plus three times the standard deviation obtained in a group of 16 healthy
HCV-seronegative controls.
The degree of CD4C-cell activation was evaluated in the same samples
and expressed as activation index (AI), calculated from the fraction of
CD25C CD4C cells found with antigen divided by that found without
Fig. 1. Representative flow cytometric analysis of CD4C-lymphocyte activation and proliferation upon stimulation of PBMCs with HCV-peptides.
PBMCs were cultured in the absence or presence of HCV-peptides for 6 days, and BrdU incorporation was allowed during the last 6 h. Cells were then
double stained with TC-conjugated anti-CD4 and PE-conjugated anti-CD25 mAbs. After cell fixation, permeabilization and partial DNA
denaturation, cells were stained with FITC-conjugated anti-BrdU mAb. 3-Colour flow cytometry was performed within 24 h. Gated on CD4C-
lymphocytes (R1), cell activation was assessed as surface expression of CD25, and proliferation was assessed as incorporation of BrdU by CD25C
cells. The degree of HCV-specific activation was expressed as activation index (AI), calculated from the fraction of CD25C CD4C cells found with
antigen divided by that found without antigen. The degree of HCV-specific proliferation was expressed as proliferation index (PI), calculated from the
fraction of CD25C/BrdUC CD4C cells found with antigen divided by that found without antigen.
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response was 1.79.
Samples with intra-assay coefficient of variation O10% were excluded
from the analysis; inter-assay variability, analyzed on three mothers and
their children at two time points over a period of 2 months, was
approximately 10%.2.5. Cytokine measurements
After secretion in the culture supernatants, cytokines may undergo
partial consumption by PBMCs. Hence, their levels were evaluated at both
day 2 and at the ending of the culture (day 6). The release of IL-2, IL-10 and
IFN-g in the supernatants was measured by specific sandwich enzyme-
linked immunosorbent assay (ELISA), by use of commercially available
pairs of monoclonal antibodies (Endogen, Woburn, MA), according to the
manufacturer’s instructions.2.6. Statistical analysis
All statistical analyses assumed a 2-sided significance level of 0.05. The
Fisher exact test and the Mann–Whitney U test were used for comparisons
between mothers and children. The paired Wilcoxon test was used to
analyze inhibition experiments. The Spearman rank test was used to
describe correlations. Data analyses were performed with Openstat3
software.3. Results
3.1. CD4C-cell proliferative responses
Proliferative response to PHA did not differ between
controls (PI, meanGSEM: 769.39G72.57), mothers
(771.75G76.25) and children (610.11G56.14), indicating
that both the HCV chronically infected mothers and their
children were immune-competent.
The analysis of the HCV-specific CD4C-cell responses
revealed that lymphocytes from children born from HCV-
infected mothers were reactive to viral peptides. In these
children, the proportion of subjects with an antigen-specific
CD4C-cell proliferative response (i.e. with PI greater than
the positive cut-off value of 2.75) to at least one HCV-
peptide was 71%, compared with 52% in the mothers and
0% in healthy controls. Fig. 2(A) shows the frequency of
subjects with positive proliferation to individual HCV-
peptides in the three groups. The proportion of responders
among children was significantly higher than among healthy
controls upon stimulation with any peptide. Also, the
frequency of children who responded to the peptide from the
Fig. 2. Presence of significant CD4C-cell proliferative response to HCV-
peptides in children vertically exposed to HCV. (A) Percentage of
subjects, in the groups of controls (white bars), mothers (gray bars) and
children (black bars), with a significant proliferation index (PI) to the
indicated HCV-peptides. A significant PI was defined as being O2.75,
which was the cut-off value calculated from the group of healthy HCV-
seronegative controls (see Section 2). P values calculated using the Fisher
exact test. (B) Intensity of CD4C-cell proliferation to the indicated HCV-
peptides in the three groups. Mean GSEM from 16 controls (white bars),
23 mothers (gray bars), and 28 children (black bars). P values calculated
using the Mann–Whitney U test. (C) Number of subjects, in the groups of
mothers (gray bars) and HCV-RNA negative children (black bars), with a
significant PI to the indicated number of peptides.
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(42.3 vs. 8.7%, PZ0.01). As shown in Fig. 2(B), similar
results were observed when the intensity of the proliferative
responses, expressed as PI, was evaluated. Children’s PIwere significantly higher compared with healthy controls in
response to all the individual peptides. The intensity of
proliferation in response to the peptide derived from HCV-
core region was significantly lower in the mothers than that
observed in children (PI, meanGSEM: 2.28G0.95 vs.
5.7G1.59, PZ0.015). The intensity of the proliferative
response to the other peptides did not significantly differ
between mothers and children. Subjects unresponsive to any
of the four peptides tested, as well as subjects with CD4C-
cells able to respond to multiple peptides (Fig. 2(C)), were
observed in both the mothers and the children groups.
However, the number of unresponsive subjects was higher
among mothers (11 of 23) than among the HCV-RNA
negative children (7 of 25); and only within the children
there were subjects whose CD4C-lymphocytes responded
to all the peptides tested. One of the three HCV-RNA
positive children was unresponsive, and two responded to a
single peptide. No correlation was observed between
CD4C-cell proliferation to any HCV-peptide and HCV-
genotype, duration of maternal infection, mode of delivery,
or type of neonatal feeding. The analysis of HCV-specific
proliferative responses in the four families with multiple
children generally showed concordance in CD4C-cell
reactivity between siblings, although lymphocyte prolifer-
ation could be directed against different viral antigens
(Fig. 3).
Inhibition experiments were performed to investigate the
possible role of IL-10 in conditioning the low proliferative
response observed in the mothers. As shown in Fig. 4,
neutralizing anti-IL-10 mAb induced a dose-dependent
increase in the percentage of proliferating CD4C-lympho-
cytes, that resulted in a significant increase of PI (PI to HCV-
core, meanGSEM: 3.72G0.85 vs. 0.50G0.11, PZ0.034; PI
to HCV-envelope: 5.11G1.87 vs. 2.17G0.80, PZ0.034).
3.2. HCV-specific CD4C-cell activation
The intensity of CD4C-activation in response to HCV-
peptides, measured as surface expression of CD25 and
expressed as AI, did not differ between mothers and children
(Fig. 5(A)). However, in the children proliferation and
activation of CD4C-cells were directly correlated upon
stimulation with all the viral peptides; on the contrary, the
same direct correlation was not observed in the mothers,
where high AI were not generally coupled with high PI
(Fig. 5(B)).
3.3. HCV-specific production of cytokines
The production of IL-2 and IFN-g did not differ
significantly between mothers and children, although
the overall production of both cytokines upon stimulation
with HCV-peptides tended to be lower in the mothers than
in their children (at day 6: IL-2 meanGSEM 25.75G
15.47 pg/ml vs. 33.59G15.97; IFN-g 84.42G26.60 vs.
178.13G61.55, PZns). However, the overall production of
Fig. 3. Analysis of HCV-specific proliferative responses in four families with more than one child. In most cases, concordance in CD4C-cell reactivity
between siblings was observed. Proliferation index (PI) to HCV-peptides from a mother (gray bars) and her multiple children (black bars) is shown.
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with HCV-peptides was significantly higher in mothers than
in children, both at day 2 (mothers 31.14G4.63 pg/ml vs.
children 9.02G2.73, PZ0.003) and at day 6 (31.88G4.67
vs. 20.53G3.24, PZ0.046). Fig. 6(A) and (B) show IL-10
production in response to the different viral peptides after 2
and 6 days of culture, respectively. As shown in Fig. 6(C)
the levels of IL-10 produced at day 2 were inversely
correlated with the intensity of the proliferative responses in
the mothers, but not in the children.4. Discussion
In this study, we evaluated HCV infection and HCV-
specific CD4C-cell reactivity in a cohort of children born
from HCV infected mothers. Our results clearly indicate
that, despite the absence of anti-HCV antibodies, the
majority of children (71%) born from HCV-infected
women have circulating CD4C-lymphocytes reacting
against HCV-specific antigens. This observation deserves
several considerations. First of all, as previouslydemonstrated in adults exposed to HCV and to other viral
infections [6,11], it seems to confirm that the evaluation of
T-cell reactivity may represent a useful tool in revealing
previous exposures of the host to a viral agent. Hence, T-cell
reactivity is able to detect a component of the immune
response that is not revealed when considering antibody
seroconversion solely. Second, the finding of a high rate of
HCV immunization in our children seems to indicate that
vertical exposure to HCV could be quantitatively more
frequent than what revealed by the rates of vertical
infection, defined as detection of anti-HCV antibodies.
Third, the activation of HCV-specific CD4C-cell responses
upon exposure to the virus may depend on factors related to
the virus, to the modality of viral exposure and to the host.
The relevance of the former two factors is suggested by
our observation of a general concordance in CD4C-cell
reactivity between siblings, who were probably exposed to
the same virus and with similar modalities. The influence of
host-related factors is suggested by the finding that, within
pairs of siblings with HCV-specific CD4C-cell reactivity,
responses were sometimes directed against different viral
antigens. Also, in the only case analysing three siblings, two
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Fig. 4. Contribution of IL-10 in the low proliferative responses of CD4C-lymphocytes from chronically HCV-infected mothers. PBMCs from mothers
were preincubated with neutralizing mAb against IL-10 for 30 min, and the inhibitor was left in culture for the entire stimulation period. At the end of
the culture, the cells were prepared and analyzed as described in Fig. 1. (A) Anti-IL-10 mAb induced a dose-dependent increase in the percentage of
proliferating CD4C-lymphocytes, reaching plateau at 10 mg/ml. One representative analysis of two independent experiments is shown. (B)
Proliferation index (PI) to the indicated HCV-peptides was significantly increased by 10 mg/ml anti-IL-10 mAb. MeanGSEM from four mothers.
P values calculated using the paired Wilcoxon test.
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responses while the third showed no such response. The
role of factors that are known to influence the vertical
transmission of HCV, such as maternal intravenous drug use
and HCV viral load [1,3,5,12,13], was impossible to
evaluate because only one of 23 mothers reported a history
of drug use, and quantification of HCV viraemia during
pregnancy and at delivery was unavailable in most cases.
Other factors that do not affect vertical transmission, such as
HCV genotype, duration of maternal infection, mode of
delivery and type of neonatal feeding [2,3,12–15], did not
seem to influence the development of HCV-specific CD4C-
cell reactivity in our children.
Moreover, our results suggest that the HCV-specific
immune responses observed in children, who did not show
any marker of HCV replication in most cases, are
qualitatively different from those observed in their chroni-
cally HCV-infected mothers. In fact, we observed that in
the children the proliferative responses, particularly those
against peptides derived from the HCV core region,
were more frequent and vigorous, and the activation of
CD4C-cells was directly correlated with proliferation upon
stimulation with any peptide. On the contrary, in the
mothers the proliferative responses to HCV-peptides were
less frequent, restricted to a lower number of peptides, andthe proliferation to the peptide derived from the core protein
was less intense. These findings are in accordance with
those reported in several cohorts of adults in different
clinical stages of HCV infection, demonstrating impaired
HCV-specific T-cell reactivity in chronically infected
patients, and highlighting the protective role of T-cell
responses to HCV structural proteins against the develop-
ment of chronic hepatitis [16–18]. Notably, none of the
three children with vertical HCV infection presented
lymphocyte proliferation in response to peptides from
core or envelope. In our study, the lower proliferation of
CD4C-lymphocytes from the mothers was not
accompanied by lower activation of these cells. Therefore,
CD4C-cells from the mothers appeared to respond to HCV
antigens with incomplete activation, characterized by
normal levels of IL-2 secretion and CD25 (IL-2 receptor)
expression, but low levels of proliferation. Incomplete
activation of HCV-specific T-cells in chronically infected
patients had been previously described by other Authors and
ascribed to abnormal priming of CD4CT-cells specific to
structural proteins by dendritic cells infected by HCV
[19,20]. We suggest that production of high levels of IL-10
early upon stimulation with HCV-antigens may represent
an additional mechanism underlying the incomplete acti-
vation of HCV-specific lymphocytes in chronically
Fig. 5. (A) CD4C-lymphocyte activation in response to stimulation with individual HCV-peptides. The intensity of cell activation, measured as surface
expression of CD25 on CD4C-cells and expressed as activation index (AI), did not differ between mothers and children; both mothers and children
had significantly higher AI than controls. MeanGSEM from 16 controls (white bars), 23 mothers (gray bars), and 28 children (black bars). P values
calculated using the Mann–Whitney U test. (B) Correlation between AI and proliferation index (PI) upon stimulation with individual HCV-peptides.
While in the children AI and PI were directly correlated in response to all the viral peptides, in the mothers high AI was not generally coupled with
high PI. r and P values calculated using the Spearman rank test.
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that hampers the activation of immune responses at
various levels, with a suggested role in preventing
eradication of chronic infection by intracellular pathogens
[21]. Several observations in our study seem to support a
role of IL-10 in incomplete activation. First, we observed
that the production of IL-10 in the supernatants of PBMCs
stimulated with HCV-peptides was markedly higher in the
mothers than in the children, especially in the first days of
culture. Second, we found that IL-10 production and
CD4C-cell proliferation were inversely correlated in the
mothers. Third and most relevant, we demonstrated that
neutralization of IL-10 during stimulation of PBMCs with
HCV-peptides was able to restore CD4C-lymphocyte
proliferation.
This study did not investigate the cellular sources of IL-10
and of the other investigated cytokines. However, other
Authors have demonstrated that the main source of
cytokines, in the same culture model used in our study, are
CD4C-T-cells [22, 23]. Therefore, our finding of differentcytokine levels in the culture supernatants from mothers and
children is likely to reflect a qualitative difference in CD4C-
cell responses between chronically infected and healthy
virus-exposed subjects. In this respect, we observed not only
that the production of IL-10 was markedly higher in the
mothers than in the children, but also that their IFN-g
production tended to be lower. These results are in
accordance with those reported by other Authors, describing
higher levels of IL-10 and lower levels of IFN-g in HCV
viraemic patients in comparison to individuals with serolo-
gical viral clearance [22,24]. The lower levels of IFN-g in the
cultures from mothers should be considered with the notion
that, through the production of IFN-g, CD4C-lymphocytes
mainly promote cellular immune responses and cytotoxic T-
lymphocyte activity that, in chronic HCV infection, mediate
control of viral replication. These considerations do not
exclude the possibility that immune cells other than CD4C-
lymphocytes may be affected in their ability to produce
cytokines in subjects with chronic HCV-infection. In fact,
supporting a key role of IL-10 in impairing CD4-cell
Fig. 6. In vitro production of IL-10 upon stimulation of PBMCs with individual HCV-peptides for (A) 2 days, or (B) 6 days. Mean G SEM from nine
mothers (gray bars) compared with nine children (black bars). P values calculated using the Mann–Whitney U test. (C) Correlation between IL-10
production at 2 days and proliferation index (PI), upon stimulation with individual HCV-peptides. Within the group of mothers, but not in the group
of children, the levels of IL-10 produced at day 2 were inversely correlated with the intensity of the proliferative responses. r and P values calculated
using the Spearman rank test.
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similarly observed that the production of IL-10 by dendritic
cells was higher from chronically infected subjects than from
subjects who serologically cleared the virus, and that IL-10
produced by dendritic cells was inversely correlated with
HCV-specific T-cell proliferation (manuscript in
preparation).
In conclusion, the present study provides evidence that
the majority of children born from HCV-infected women
develop antigen-specific CD4C-cell immune responses,
which are likely to have a protective role against infection.
It is possible that the modality of viral exposure, possibly
contact with the virus in presence of maternal anti-HCV
antibodies, could prevent successful infection in most of
these children. Further studies planned to characterize
CD4C-cell reactivity at different time-points from birth
would be of value to better define the mechanisms
underlying this phenomenon.References
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